Canadian Online Pharmacy

Drug Information Update - Public Notification: Jimpness Beauty Fat Loss Capsules contain hidden drug ingredients

FDA Division of Drug Information: Know the Moment It Happens

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.


The Food and Drug Administration (FDA) is advising consumers not to purchase or use Jimpness Beauty Fat Loss Capsules, a product promoted and sold for weight loss on various websites, including www.jimpness.net .

FDA laboratory analysis confirmed that Jimpness Beauty Fat Loss Capsules contain sibutramine, phenolphthalein, and sildenafil.  

Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.

For more information please visit: Jimpness

 


 

This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.

 


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery